...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Biogen looks to FDA for approval of early Alzheimers drug.

"I interpreted that to suggest that the trial failed on purely statistical grounds...i.e. more patient years would have got us to meeting endpoints.  How else can one interpret it?"

All we know for sure is that BETonMACE failed to meet statistical significance (p<0.05) for the primary endpoint. Anything beyond that is uncertain. Your interpretation is only one of many many possible outcomes. 

BDAZ

Share
New Message
Please login to post a reply